

Recce to Give Opening R&D Address at 2019 World Antibiotic Resistance Congress

**Dr John Prendergast will showcase the potential of
New Synthetic Antibiotics**

SYDNEY, Australia, 1 August 2019: Recce Pharmaceuticals Ltd (ASX: RCE) (**Company**), the Company pioneering the development of a new class of synthetic antibiotics, today announced that it will be delivering an Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress in Washington D.C., 7-8 November 2019.

The two-day World AMR Congress is the largest commercially focused conference with AMR at its centre, engaging more than 600 attendees from over 40 countries. It attracts key stakeholders from the pharma and biotech industry who are involved in the development of antimicrobial drugs and diagnostics, including healthcare payers, regulators and partners.

André Singer, General Manager, World Anti-Microbial Resistance Congress says:

“We are proud to provide this platform for promising antibiotic programs to be introduced to the AMR community, such as Recce Pharmaceuticals’ synthetic polymer program which has the potential of transforming the way superbugs are targeted, through a new class of broad-spectrum antibiotics.”

Recce Chairman Dr. John Prendergast will give the 20-minute Opening Address, during which he will highlight the urgent need for new antibiotics to address AMR. The presentation will also afford the opportunity to provide an overview and update of Recce’s antibiotics pipeline as well as answer “***How synthetic antibiotic development can change the antibiotic treatment model***”.



ASX: RCE

Head Office: Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (02) 8075 4585 **F** +61 (02) 8075 4584

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

“While addressing the key hurdles in antibiotic R&D such as push and pull incentives needed to reignite the sector, it is crucial to showcase ground-breaking antibiotic programs targeting a critical unmet medical need despite the current challenges to bring these therapies to the market” says **Singer**.

Recce’s patented lead antibiotic candidate RECCE® 327 has been designed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria, including their superbug forms. The US FDA awarded RECCE® 327 a Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling RECCE® 327 for Fast Track designation. It is in the final stages of pre-clinical development to start a Phase I clinical trial.

Dr. Prendergast stated: “The rapid emergence and dissemination of antimicrobial-resistant microorganisms in ICUs and hospitals worldwide constitute a problem of crisis dimensions. The need for innovation in this space is essential and we are encouraged by the recent growing interest in our new class of broad-spectrum antibiotic. Moreover, we are delighted to present at the World Congress since it provides an opportunity for Recce to engage with other industry leaders to discuss the most efficient commercial and clinical pathways to address the growing global threat from antibiotic resistance.”

Prior to the Congress, Recce will publish a white paper summarising its data on RECCE® 327 and looks forward to meeting delegates and industry at its booth at the event. For more details, please visit the World AMR Congress website.



For further information please visit www.recce.com.au or contact:

Investor Relations

James Graham
Executive Director
Recce Pharmaceuticals Ltd
Tel: +61 (02) 8075 4585

Media (Australia)

Andrew Geddes
CityPR
Tel: +61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media (International)

Sue Charles/Genevieve Wilson
Instinctif Partners
Tel: +44 (0)20 7866 7863
E: recce@instinctif.com



About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development of a New Class of Synthetic Antibiotics with Broad Spectrum activity, addressing the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate RECCE® 327 has been designed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. The FDA awarded RECCE® 327 Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling RECCE® 327 for Fast Track designation, plus 10 years of market exclusivity post approval. Recce's expanding anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

For further information please visit www.recce.com.au or contact:

Investor Relations

James Graham
Executive Director
Recce Pharmaceuticals Ltd
Tel: +61 (02) 8075 4585

Media (Australia)

Andrew Geddes
CityPR
Tel: +61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media (International)

Sue Charles/Genevieve Wilson
Instinctif Partners
Tel: +44 (0)20 7866 7863
E: recce@instinctif.com

